Free Trial
→ The Social Security Changes No One’s Talking About (From Altimetry) (Ad)
NASDAQ:RENB

Renovaro 11/14/2023 Earnings Report

Renovaro logo
$0.31 -0.01 (-1.59%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$0.32 +0.01 (+1.94%)
As of 05/30/2025 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings History

Renovaro EPS Results

Actual EPS
-$0.14
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Renovaro Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Renovaro Announcement Details

Quarter
Date
11/14/2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Renovaro Earnings Headlines

Renovaro Inc. Secures Ruling to Expedite Trial Against Predictive Oncology Over Breach of Merger Agreement
May 24, 2025 | nasdaq.com
Renovaro Inc. Accelerates 2025 Lawsuit to Force Predictive Oncology Merger
May 22, 2025 | insidermonkey.com
"I'm risking my reputation on this"
Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.
June 1, 2025 | Crypto 101 Media (Ad)
UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
May 22, 2025 | globenewswire.com
Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology
May 22, 2025 | globenewswire.com
Renovaro partners with Amsterdam UMC on cancer diagnostics
May 15, 2025 | uk.investing.com
See More Renovaro Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Renovaro? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Renovaro and other key companies, straight to your email.

About Renovaro

Renovaro (NASDAQ:RENB), a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.

View Renovaro Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles